Body awareness, arm function, and quality of life in women after breast cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will compare women aged 25–75 who completed primary treatment for Stage 0–III breast cancer within the last six months to age- and BMI-matched healthy controls. Participants will attend in-person visits at Halic University and Yeditepe Hospital in Istanbul for standardized tests of upper extremity function, validated body-awareness questionnaires, and quality-of-life measures between May and October 2025. Key exclusions include recent neuromuscular disorders, recent upper-extremity/thoracic/cervical rehabilitation, or medications that affect neuromuscular performance. Results will be used to quantify treatment-related functional and perceptual changes and to inform post-treatment follow-up and rehabilitation priorities.

Why it matters

Who can join: the full rules

Inclusion Criteria for breast cancer survivors:

* Being a woman
* Being between the ages of 25 and 75
* Having been diagnosed with Stage 0-III breast cancer
* Having completed primary treatments (surgery, chemotherapy, and/or radiation therapy) no more than 6 months prior to the assessment date
* Having received medical clearance from a physician
* Having undergone either breast-conserving surgery or mastectomy due to breast cancer
* Willingness to participate in the study voluntarily

Exclusion Criteria for breast cancer survivors:

* Having a history of rehabilitation due to upper extremity, thoracic, or cervical musculoskeletal disorders within 6 months prior to the breast cancer diagnosis
* Having a history of neuromuscular dysfunction
* Using medications that may affect neuromuscular performance

Inclusion criteria for the control group:

* Being a woman
* Having a body mass index (BMI) within ±3 kg/m² of the breast cancer survivor group
* Being within ±5 years of age compared to the breast cancer survivor group
* Matching hand dominance with the breast cancer survivor group

Exclusion criteria for the control group:

* Having a history of neuromuscular dysfunction
* Using medications that may affect neuromuscular performance
* Having a history of rehabilitation due to upper extremity, thoracic, or cervical musculoskeletal disorders within the last 6 months

Where it's running

• Halic University
  Istanbul, Turkey (Türkiye) Recruiting
• Yeditepe Hospital
  Istanbul, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Seda Saka, PhD
• Email: sedasaka@halic.edu.tr
• Phone: 05447803417

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Oncoliq blood test for early detection of breast cancer

  This project will test whether a blood-based miRNA panel (the Oncoliq Test) can detect early breast cancer in adults 40–70 by comparing newly diagnosed, untreated patients with cancer-free controls.

  Recruiting Oncoliq US Inc · Buenos Aires, Buenos Aires · NCT07331506

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• Negative pressure wound therapy after mastectomy

  This study tests whether a negative pressure dressing after mastectomy reduces fluid build‑up and common wound complications in women with breast cancer.

  Recruiting Dalarna County Council, Sweden · Falun · NCT07607366

• ATUSA 3D automated breast ultrasound for suspicious breast lesions

  This study will test whether the ATUSA 3D automated breast ultrasound system can produce high-quality images that match biopsy results in women with BI-RADS 4 or 5 breast findings.

  Recruiting at 2 sites iSono Health, Inc. · Sacramento, California and 1 other locations · NCT07505797

• Support tool for women with HR+ breast cancer on long-term endocrine therapy

  This study tests a SHIELD web- and app-based portal to help women with hormone receptor–positive breast cancer manage symptoms while on long-term endocrine treatment.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07482384

• Conformal ablative radiotherapy for older women with localized ER-positive, HER2-negative breast cancer choosing non-surgical care

  This study will test whether five focused SABR treatments can control ER-positive, HER2-negative breast tumors up to 5 cm in women aged 65 and older who are opting for non-surgical management.

  Recruiting University of Kansas Medical Center · Kansas City, Kansas and 1 other locations · NCT07242118

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.